Crinetics Pharmaceuticals Inc.

33.23-0.2700-0.81%Vol 1.09M1Y Perf 84.67%
Dec 6th, 2023 16:00 DELAYED
BID31.63 ASK34.96
Open33.75 Previous Close33.50
Pre-Market- After-Market33.19
 - -  -0.04 -0.12%
Target Price
38.50 
Analyst Rating
Strong Buy 1.00
Potential %
15.86 
Finscreener Ranking
★★+     47.16
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★     55.76
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★+     42.70
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
96.67 
Earnings Rating
Neutral
Market Cap2.22B 
Earnings Date
13th Nov 2023
Alpha0.01 Standard Deviation0.16
Beta0.56 

Today's Price Range

33.1034.09

52W Range

15.2333.85

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
4.53%
1 Month
12.57%
3 Months
105.63%
6 Months
50.36%
1 Year
84.67%
3 Years
140.10%
5 Years
-0.18%
10 Years
-

TickerPriceChg.Chg.%
CRNX33.23-0.2700-0.81
AAPL192.32-1.1000-0.57
GOOG131.43-0.9600-0.73
MSFT368.81-3.7150-1.00
XOM99.11-1.3300-1.32
WFC44.500.01000.02
JNJ156.62-1.9300-1.22
FB196.640.99000.51
GE119.81-0.4200-0.35
JPM156.31-1.6600-1.05
Financial StrengthValueIndustryS&P 500US Markets
15.10
15.40
0.01
0.01
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-2 961.50
-2 943.10
-22 521.60
-
RevenueValueIndustryS&P 500US Markets
4.03M
0.07
-40.33
-21.29
Earnings HistoryEstimateReportedSurprise %
Q03 2023-0.89-1.01-13.48
Q02 2023-0.85-0.94-10.59
Q01 2023-0.82-0.85-3.66
Q04 2022-0.82-0.84-2.44
Q03 2022-0.78-0.780.00
Q02 2022-0.62-0.81-30.65
Q01 2022-0.56-0.73-30.36
Q04 2021-0.57-0.68-19.30
Earnings Per EndEstimateRevision %Trend
12/2023 QR-0.903.23Positive
12/2023 FY-3.660.54Positive
3/2024 QR-0.890.00-
12/2024 FY-3.4610.13Positive
Next Report Date-
Estimated EPS Next Report-0.89
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume1.09M
Shares Outstanding66.80K
Shares Float53.91M
Trades Count10.72K
Dollar Volume36.56M
Avg. Volume1.03M
Avg. Weekly Volume798.81K
Avg. Monthly Volume734.51K
Avg. Quarterly Volume1.56M

Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) stock closed at 33.23 per share at the end of the most recent trading day (a -0.81% change compared to the prior day closing price) with a volume of 1.09M shares and market capitalization of 2.22B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 68 people. Crinetics Pharmaceuticals Inc. CEO is R. Scott Struthers.

The one-year performance of Crinetics Pharmaceuticals Inc. stock is 84.67%, while year-to-date (YTD) performance is 81.58%. CRNX stock has a five-year performance of -0.18%. Its 52-week range is between 15.23 and 33.85, which gives CRNX stock a 52-week price range ratio of 96.67%

Crinetics Pharmaceuticals Inc. currently has a PE ratio of -5.90, a price-to-book (PB) ratio of 2.71, a price-to-sale (PS) ratio of 223.36, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -53.26%, a ROC of -55.09% and a ROE of -58.10%. The company’s profit margin is -%, its EBITDA margin is -2 943.10%, and its revenue ttm is $4.03 Million , which makes it $0.07 revenue per share.

Of the last four earnings reports from Crinetics Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.89 for the next earnings report. Crinetics Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Crinetics Pharmaceuticals Inc. is Strong Buy (1), with a target price of $38.5, which is +15.86% compared to the current price. The earnings rating for Crinetics Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Crinetics Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Crinetics Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 8.56, ATR14 : 1.51, CCI20 : 115.38, Chaikin Money Flow : 0.11, MACD : 1.28, Money Flow Index : 79.89, ROC : 10.80, RSI : 65.20, STOCH (14,3) : 86.86, STOCH RSI : 0.73, UO : 55.36, Williams %R : -13.14), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Crinetics Pharmaceuticals Inc. in the last 12-months were: Betz Stephen (Sold 20 714 shares of value $446 028 ), Coelho Rogerio Vivaldi (Buy at a value of $110 300), Dana Pizzuti (Sold 8 212 shares of value $132 624 ), Krasner Alan (Sold 0 shares of value $-84 070 ), Krasner Alan (Sold 7 000 shares of value $210 000 ), Marcus Wilson (Sold 0 shares of value $-278 400 ), Marcus Wilson (Sold 40 922 shares of value $904 903 ), Stephen F. Betz (Sold 20 840 shares of value $400 524 ), Struthers Richard (Sold 0 shares of value $-1 970 600 ), Struthers Richard (Sold 200 000 shares of value $6 111 440 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
10 (100.00 %)
9 (100.00 %)
8 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

CEO: R. Scott Struthers

Telephone: +1 858 450-6464

Address: 10222 Barnes Canyon Road, San Diego 92121, CA, US

Number of employees: 68

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

65%35%

Bearish Bullish

53%47%

 

News

Stocktwits